Increased Incidence of Severe Gastrointestinal Events With First-Line Paclitaxel, Carboplatin, and Vorinostat Chemotherapy for Advanced-Stage Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Cancer - Mendivil, Alberto A.; Micha, John P.; Brown, John V.; Rettenmaier, Mark A.; Abaid, Lisa N.; Lopez, Katrina L.; Goldstein, Bram H. (International journal of gynecological cancer, 2013)
Keywords: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Carboplatin; Carboplatin - administration & dosage; Chemotherapy; Cystadenocarcinoma, Serous - drug therapy; Cystadenocarcinoma, Serous - mortality; Cystadenocarcinoma, Serous - pathology; Endometrial Neoplasms - drug therapy; Endometrial Neoplasms - mortality; Endometrial Neoplasms - pathology; Fallopian Tube Neoplasms - drug therapy; Fallopian Tube Neoplasms - mortality; Fallopian Tube Neoplasms - pathology; Female; Follow-Up Studies; Gastrointestinal Diseases - chemically induced; Gastrointestinal Diseases - epidemiology; Genital cancers; Gynecologic oncology; Gynecological cancer; Humans; Hydroxamic Acids - administration & dosage; Incidence; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Ovarian cancer; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - mortality; Ovarian Neoplasms - pathology; Ovaries; Paclitaxel; Paclitaxel - administration & dosage; Peritoneal Neoplasms - drug therapy; Peritoneal Neoplasms - mortality; Peritoneal Neoplasms - pathology; Prognosis; Prospective Studies; Response rates; Survival Rate; Vorinostat; Carboplatin; Gynecologic oncology; Chemotherapy; Vorinostat; Paclitaxel; Ovarian cancer